Cytek Biosciences Stock Performance
| CTKB Stock | USD 4.20 0.14 3.45% |
The firm shows a Beta (market volatility) of 0.28, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cytek Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cytek Biosciences is expected to be smaller as well. At this point, Cytek Biosciences has a negative expected return of -0.63%. Please make sure to confirm Cytek Biosciences' accumulation distribution, and the relationship between the potential upside and day median price , to decide if Cytek Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Cytek Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's forward-looking signals remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 167.6 M | |
| Free Cash Flow | 21.9 M |
Cytek |
Cytek Biosciences Relative Risk vs. Return Landscape
If you would invest 646.00 in Cytek Biosciences on December 22, 2024 and sell it today you would lose (226.00) from holding Cytek Biosciences or give up 34.98% of portfolio value over 90 days. Cytek Biosciences is currently does not generate positive expected returns and assumes 4.0974% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Cytek, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cytek Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytek Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cytek Biosciences, and traders can use it to determine the average amount a Cytek Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1527
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CTKB |
Estimated Market Risk
| 4.1 actual daily | 36 64% of assets are more volatile |
Expected Return
| -0.63 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cytek Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cytek Biosciences by adding Cytek Biosciences to a well-diversified portfolio.
Cytek Biosciences Fundamentals Growth
Cytek Stock prices reflect investors' perceptions of the future prospects and financial health of Cytek Biosciences, and Cytek Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cytek Stock performance.
| Return On Equity | -0.0153 | ||||
| Return On Asset | -0.0291 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 259.23 M | ||||
| Shares Outstanding | 128.1 M | ||||
| Price To Book | 1.31 X | ||||
| Price To Sales | 2.59 X | ||||
| Revenue | 200.45 M | ||||
| EBITDA | (20.52 M) | ||||
| Cash And Equivalents | 349.89 M | ||||
| Cash Per Share | 2.60 X | ||||
| Total Debt | 7.55 M | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 3.06 X | ||||
| Cash Flow From Operations | 25.38 M | ||||
| Earnings Per Share | (0.05) X | ||||
| Total Asset | 499.5 M | ||||
| Retained Earnings | (35.2 M) | ||||
About Cytek Biosciences Performance
By analyzing Cytek Biosciences' fundamental ratios, stakeholders can gain valuable insights into Cytek Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cytek Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cytek Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California. Cytek Biosciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 555 people.Things to note about Cytek Biosciences performance evaluation
Checking the ongoing alerts about Cytek Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cytek Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cytek Biosciences generated a negative expected return over the last 90 days | |
| Cytek Biosciences has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 200.45 M. Net Loss for the year was (6.02 M) with profit before overhead, payroll, taxes, and interest of 111.11 M. | |
| About 61.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Cytek Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cytek Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Cytek Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cytek Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cytek Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cytek Biosciences' stock. These opinions can provide insight into Cytek Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cytek Stock analysis
When running Cytek Biosciences' price analysis, check to measure Cytek Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytek Biosciences is operating at the current time. Most of Cytek Biosciences' value examination focuses on studying past and present price action to predict the probability of Cytek Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytek Biosciences' price. Additionally, you may evaluate how the addition of Cytek Biosciences to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |